Spanish study reveals Real-World impact of COPD drug trixeo

NCT ID NCT06321731

Completed Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jan 04, 2026 · Last updated May 23, 2026 · Updated 20 times

Summary

This study looked back at the medical records of 718 adults with COPD in Spain who started taking the triple-combination inhaler Trixeo. Researchers wanted to see how many lung flare-ups (exacerbations) patients had in the year after starting the drug. The goal was to understand the real-world benefits and patient characteristics, not to test a new treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Research Site

Barcelona, Spain
Research Site

Granada, Spain
Research Site

Lleida, Spain
Research Site

Lugo, Spain
Research Site

Madrid, Spain
Research Site

Málaga, Spain
Research Site

Murcia, Spain
Research Site

Ourense, Spain
Research Site

Oviedo, Spain
Research Site

Palma de Mallorca, Spain
Research Site

Santa Cruz de Tenerife, Spain
Research Site

Seville, Spain
Research Site

Valencia, Spain
Research Site

Vitoria-Gasteiz, Spain
Research Site

Zaragoza, Spain

Conditions

Explore the condition pages connected to this study.

CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)